GENETCO, Inc., is a long-established pharmaceutical wholesale distributor headquartered in Ronkonkoma, New York. The business is being offered through an expedited, competitive Chapter 11 sale process, subject to Bankruptcy Court approval.
GENETCO represents an opportunity to acquire an existing national pharmaceutical distribution platform rather than undertake the time, cost, and regulatory burden of building one from the ground up. The company has more than 40 years of operating history and maintains wholesale pharmaceutical distribution licenses in 49 states, together with a DEA Controlled Substance Registration, NABP accreditation, established compliance systems, operating procedures, industry relationships, and existing warehouse and distribution infrastructure.
The transaction is expected to be structured through a stock sale or stock transfer, allowing the licensed operating entity to remain in existence after closing. While any buyer will remain responsible for satisfying applicable federal, state, and accreditation requirements associated with a change in ownership or control, the proposed structure is intended to preserve continuity of the existing regulated business and provide an accelerated path to market.
Executive Summary:
Investment Opportunity: GENETCO is a deeply distressed pharmaceutical distributor that has already contracted from more than $20 million in annual revenue to approximately $1 million. Inventory has been reduced to roughly $250,000 and the business is operating from a significantly smaller cost base. Rather than funding a turnaround of an oversized organization, an investor has the opportunity to rebuild an existing licensed distribution platform with established industry knowledge, operating systems, and customer relationships.
Strategic Objective: The goal is to rebuild GENETCO into a focused regional distributor of generic pharmaceuticals with annual revenue of approximately $20 million within five years. The financial model targets a sustainable 28% gross margin, approximately 7% EBITDA margin, six annual inventory turns, and disciplined 30-day accounts receivable and accounts payable cycles.
Turnaround Strategy: The turnaround is based on five initiatives: restore supplier relationships, recruit and incentivize experienced sales professionals, concentrate on profitable generic products, implement disciplined purchasing and inventory management, and maintain rigorous cash management through a rolling 13-week cash flow forecast. Growth will be staged to preserve liquidity and avoid overextending working capital.
Financial Outlook: Revenue is projected to increase progressively from approximately $1 million to $3 million, $6 million, $10 million, $15 million, and ultimately $20 million. As fixed overhead is leveraged across higher sales, EBITDA is expected to improve steadily while inventory, receivables, and payables remain tightly managed through an integrated operating model.
Capital Use and Risk Management: Capital will primarily fund working capital, including inventory purchases and accounts receivable generated by growth. The model identifies expected funding needs, peak cash requirements, and the point at which operations become self-funding. Management reporting will emphasize gross margin, EBITDA, inventory turns, cash conversion, and customer profitability.
Investment Thesis: The value proposition is not based on financial engineering but on rebuilding a viable operating business. If management executes successfully, investors should own a scalable pharmaceutical distribution platform with improving cash generation, expanding EBITDA, and meaningful enterprise value creation.
Additional Information:
The opportunity may be particularly attractive to:
- Regional and national pharmaceutical wholesalers
- Generic and specialty pharmaceutical manufacturers
- International pharmaceutical companies seeking U.S. market entry
- Specialty distributors
- Healthcare logistics and distribution companies
- Healthcare-focused private equity firms and portfolio companies
A strategic buyer may be able to use GENETCO to expand geographic reach, acquire additional licenses, broaden customer access, improve purchasing leverage, establish direct distribution capabilities, or integrate specialty or generic pharmaceutical products into an existing platform. Potential synergies may include purchasing efficiencies, inventory optimization, logistics integration, technology consolidation, sales-force expansion, cross-selling, and the elimination of duplicative overhead.
GENETCO’s recent operating performance reflects working-capital constraints and industry consolidation, but the company’s core regulatory platform, operating infrastructure, customer relationships, supplier relationships, and industry knowledge remain central to the acquisition thesis. The opportunity should therefore be evaluated as the acquisition of a licensed national distribution platform—not merely the purchase of inventory or a distressed wholesale operation.
Qualified prospective purchasers will be invited to:
- Execute a confidentiality agreement
- Receive access to a virtual data room
- Conduct management discussions and due diligence
- Submit a qualified bid
- Participate in an auction, if necessary
- Acquire the business through a court-approved transaction
Due diligence is available immediately, and the sale process is expected to proceed on an expedited basis. Closing is anticipated within approximately 30 days, subject to the confirmed Chapter 11 plan, definitive transaction documents, and court approval.
Highest Current Offer is only $265,000. This is an incredible opportunity!!!
Please Click Here to Complete the NDA for Data Room Access
ONLINE BIDDING ONLY – CLICK HERE FOR ONLINE BIDDING
Bidding is available by computer (PC or Mac Only) or download of the Maltz Auctions App on the App Store or Google Play (Required for tablet and Cell Phone Devices)
Pre-Registration Required to Bid. You Must send in signed Terms & Conditions of Sale, signed Online Bidding Form and a deposit (cashier’s check only) to be approved for bidding.
*Sale subject to further court approval
